目的 探討喘舒片聯(lián)合沙美特羅替卡松治療支氣管哮喘急性發(fā)作期的臨床療效。方法 選取2021年10月—2023年11月定州市人民醫(yī)院收治的支氣管哮喘癥患者120例。依據(jù)用藥情況分為對照組和治療組，每組各60例。對照組患者吸入沙美特羅替卡松吸入氣霧劑，1撳/次，2次/d。在對照組的基礎(chǔ)上，治療組口服喘舒片，2片/次，3次/d；兩組用藥7 d觀察治療情況。觀察兩組患者臨床療效，比較治療前后兩組患者癥狀好轉(zhuǎn)時間，哮喘控制試驗評分（ACT）和哮喘生活質(zhì)量評分量表（AQLQ）評分，及血管內(nèi)皮生長因子（VEGF）、血管細(xì)胞黏附分子（VCAM-1）、C反應(yīng)蛋白（CRP）、呼氣一氧化氮（FeNO）水平、用力肺活量（FVC）、第1秒用力呼氣量（FEV1）和第1秒用力呼氣容積占用力肺活量百分比（FEV1/FVC）指標(biāo)水平。結(jié)果 治療后，治療組臨床總有效率為96.67%，明顯高于對照組（83.33%，P＜0.05）。治療后，治療組咳嗽、喘息、胸痛、氣促等癥狀好轉(zhuǎn)時間均明顯早于對照組（P＜0.05）。治療后，兩組患者ACT評分、AQLQ評分比治療前均明顯升高（P＜0.05），且治療組ACT評分、AQLQ評分均明顯高于對照組（P＜0.05）。治療后，兩組患者VEGF、VCAM-1、CRP、FeNO水平比治療前明顯降低，而FVC、FEV1、FEV1/FVC水平明顯升高（P＜0.05），且治療組患者上述指標(biāo)水平明顯好于對照組（P＜0.05）。結(jié)論 喘舒片聯(lián)合沙美特羅替卡松可極大改善哮喘急性發(fā)作期患者癥狀，減弱機(jī)體內(nèi)炎性反應(yīng)，顯著提升生活質(zhì)量。

Objective To explore the clinical effect of Chuanshu Tablets combined with Salmeterol Xinafoate and Fluticasone Propionate Inhalation Aerosol in treatment of bronchial asthma. Methods Patients (120 cases) with bronchial asthma in Dingzhou People's Hospital from October 2021 to November 2023were randomly divided into control and treatment group, and each group had 60 cases. Patients in the control group were administered with Salmeterol Xinafoate and Fluticasone Propionate Inhalation Aerosol, 1 press/time, twice daily. Patients in the treatment group were po administered with Chuanshu Tablets on the basis of the control group, 2 tablets/time, three times daily. Patients in two groups were treated for 7 d. After treatment, the clinical evaluations were evaluated, the symptom relief time, the scores of ACT and AQLQ, and the levels of VEGF, VCAM-1, CRP, FeNO, FVC, FEV1 and FEV1/FVC in two groups before and after treatment were compared. Results After treatment, the clinical effective rate of the treatment group was 96.67%, which was significantly higher than that of the control group (83.33%, P < 0.05). After treatment, the improvement time of cough, wheezing, chest pain and shortness of breath in the treatment group was significantly earlier than that in the control group (P < 0.05). After treatment, ACT scores and AQLQ scores of the two groups were significantly higher than those before treatment (P < 0.05), and ACT scores and AQLQ scores of the treatment group were significantly higher than those of the control group (P < 0.05). After treatment, the levels of VEGF, VCAM-1, CRP and FeNO in two groups were significantly lower than those before treatment, while the levels of FVC, FEV1 and FEV1/FVC were significantly increased (P < 0.05), and the above-mentioned indexes in the treatment group were significantly better than those in the control group (P < 0.05). Conclusion Salmeterol fluticasone combined with Chuanshu Tablets can greatly improve the symptoms of patients with acute asthma, reduce the inflammatory response in the body, and significantly improve the quality of life.

R974

河北省醫(yī)學(xué)科學(xué)研究課題計劃項目（20191747）